100 Recruiting Studies Using Durvalumab

Active clinical trials that use this intervention, sourced directly from the NIH registry.

Browse by condition

Trials Using Durvalumab

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

SIRT With Tremelimumab and Durvalumab for Resectable HCC

📍 Cedars-Sinai Medical Center — Los Angeles, California

Resectable Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

📍 University of California, San Diego — San Diego, California

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

📍 City of Hope Medical Center — Duarte, California

BCLC Stage B Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California

Locally Advanced Pancreatic Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

📍 Research Site — Tucson, Arizona

Triple Negative Breast Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

📍 Tom Baker Cancer Centre — Calgary, Alberta

Bladder Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

📍 Research Site — Baltimore, Maryland

Gastric Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

📍 M D Anderson Cancer Center — Houston, Texas

Stage III Fallopian Tube Cancer AJCC v7

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

📍 Research Site — Foothill Ranch, California

Advanced Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

📍 Research Site — Phoenix, Arizona

Non Small Cell Lung Cancer NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

TheraSphere With Durvalumab and Tremelimumab for HCC

📍 University of California San Diego — San Diego, California

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

📍 City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California

Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

📍 Research Site — Duarte, California

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

📍 Research Site — San Diego, California

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

📍 Research Site — Iowa City, Iowa

Metastatic Non-Small Cell Lung Cancer (NSCLC)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

📍 Research Site — Anaheim, California

Non Small Cell Lung Carcinoma NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

📍 Research Site — Gilbert, Arizona

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

📍 Research Site — Tucson, Arizona

Endometrial Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Locally Advanced Bladder Urothelial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

📍 The Ottawa Hospital Cancer Centre — Ottawa, Ontario

Gynaecological Cancers

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

📍 Tom Baker Cancer Centre — Calgary, Alberta

Solid Malignancies

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

📍 Research Site — Tucson, Arizona

Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Clear Cell Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

📍 NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

Lung Non-Small Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

📍 Research Site — Costa Mesa, California

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

📍 Washington University School of Medicine — St Louis, Missouri

Primary Central Nervous System Lymphoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

📍 Northwest Cancer Specialists, P.C. — Tigard, Oregon

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

📍 Research Site — Los Angeles, California

Biliary Tract Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California

Bladder Urothelial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

📍 Research Site — Birmingham, Alabama

Unresectable Locally Advanced Urothelial Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of AZD2811 + Durvalumab in ES-SCLC

📍 Research Site — Grand Rapids, Michigan

Small-Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

📍 Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

📍 Research Site — Commack, New York

Metastatic Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Bladder Urothelial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

📍 Research Site — La Jolla, California

Locally Advanced or Metastatic Solid Tumours

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

📍 Research Site — Phoenix, Arizona

NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

📍 Research Site — La Jolla, California

Advanced or Metastatic NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

📍 Research Site — Daphne, Alabama

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California

Metastatic Malignant Female Reproductive System Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

📍 Indiana University — Bloomington, Indiana

Urothelial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

📍 University of Kansas Cancer Center - Overland Park — Overland Park, Kansas

Advanced Biliary Tract Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

📍 Research Site — Duarte, California

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

📍 Research Site — Beijing,

Carcinoma, Non-Small-Cell Lung

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey

Germ Cell Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

📍 Research Site — The Bronx, New York

Non-small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

📍 Los Angeles General Medical Center — Los Angeles, California

Advanced Malignant Skin Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

📍 Research Site — Orange, California

Muscle Invasive Bladder Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

📍 M D Anderson Cancer Center — Houston, Texas

Extensive Stage Lung Small Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

📍 Research Site — Tuscaloosa, Alabama

Carcinoma, Non-Small-Cell Lung

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

📍 Research Site — Los Angeles, California

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

📍 Research Site — Birmingham, Alabama

Small Cell Lung Carcinoma Extensive Disease

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

📍 Washington University School of Medicine — St Louis, Missouri

Extensive-stage Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Small Cell Lung Cancer Extensive Stage

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

📍 Research Site — Birmingham, Alabama

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Prostate Cancer Biomarker Enrichment and Treatment Selection

📍 Cross Cancer Institute — Edmonton, Alberta

Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

📍 Mayo Clinic of Scottsdale — Phoenix, Arizona

Cholangiocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

📍 Research Site — Fort Myers, Florida

Metastatic Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

📍 Research Site — Anaheim, California

Non Small Cell Lung Carcinoma NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

📍 NorthWestern University — Chicago, Illinois

Stage IIIA Non-small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

📍 Research Site — Phoenix, Arizona

Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

📍 Baptist Alliance - McI — Miami, Florida

NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey

Pancreatic Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

📍 Research Site — Beverly Hills, California

Carcinoma, Non-Small-Cell Lung

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

📍 University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California

Extensive Stage Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

📍 Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill — Chapel Hill, North Carolina

Carcinoma, Squamous Cell

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Endometrial Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

📍 Princess Margaret Cancer Centre — Toronto, Ontario

Glioma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

📍 University of Florida Health Science Center - Jacksonville — Jacksonville, Florida

Stage II Non-Small Cell Lung Cancer AJCC v7

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Metastatic Colorectal Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

📍 Research Site — Mobile, Alabama

Advanced or Metastatic Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

📍 Infirmary Cancer Center — Mobile, Alabama

Extensive-Stage Small-Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey

Esophageal Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

📍 Cliniques Universitaires Saint-Luc — Brussels,

Oropharyngeal Squamous Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

📍 University of Illinois Medical Center — Chicago, Illinois

Extensive Stage Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

📍 Keck Medicine of USC Buena Park — Buena Park, California

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

📍 Campbelltown Hospital — Campbelltown, New South Wales

Lung Cancer Metastatic

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

📍 Research Site — Aurora, Colorado

Hepatocellular Carcinoma (HCC)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Durvalumab and Tremelimumab for Pediatric Malignancies

📍 Research Site — Baltimore, Maryland

Pediatric Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

📍 University Of Alabama At Birmingham — Birmingham, Alabama

Larynx

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

📍 M D Anderson Cancer Center — Houston, Texas

Borderline Resectable Pancreatic Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

📍 Research Site — Phoenix, Arizona

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

📍 Research Site — Chandler, Arizona

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

📍 M D Anderson Cancer Center — Houston, Texas

Metastatic Angiosarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey

Thyroid Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

📍 Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah

Infiltrating Urothelial Carcinoma, Sarcomatoid Variant

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Hepatocellular Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

📍 Baptist Alliance Miami Cancer Institute — Miami, Florida

Non Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

📍 University of Alabama at Birmingham — Birmingham, Alabama

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

📍 Research Site — Mobile, Alabama

Biliary Tract Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

📍 Research Site — Boston, Massachusetts

Papillary Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

📍 Houston Methodist Cancer Center — Houston, Texas

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

📍 Research Site — Atlanta, Georgia

Esophageal Squamous Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

📍 Research Site — Auchenflower,

Non-muscle-invasive Bladder Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

📍 Research Site — Birmingham, Alabama

Urinary Bladder Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Colorectal Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

📍 Research Site — Bonita Springs, Florida

Non-small Cell Lung Cancer NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Recurrent Lung Non-Small Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

📍 Research Site — La Jolla, California

Advanced Hepatocellular Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

📍 Research Site — Los Angeles, California

Metastatic Microsatellite-stable Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

📍 University of South Alabama, Mitchell Cancer Institute ( Site 0003) — Mobile, Alabama

Lung Neoplasms

View Study & Checklist ➔